Clinical Scorecard: Cardiovascular Implications in Ankylosing Spondylitis and Axial Spondyloarthritis: A Review of Epidemiology, Pathophysiology, and Treatment Approaches
At a Glance
Category
Detail
Condition
Ankylosing Spondylitis and Axial Spondyloarthritis
Key Mechanisms
Chronic inflammation leading to cardiovascular injury through endothelial dysfunction, oxidative stress, and atherosclerosis.
Target Population
Patients with Ankylosing Spondylitis and Axial Spondyloarthritis, particularly those with high inflammatory activity.
Care Setting
Rheumatology and cardiovascular care settings.
Key Highlights
Increased risk of myocardial infarction, stroke, and atrial fibrillation in AS/axSpA patients.
Subclinical vascular abnormalities are common even before overt cardiovascular symptoms.
Tumor necrosis factor inhibitors may provide cardiovascular benefits by controlling inflammation.
Guideline-Based Recommendations
Diagnosis
Assess cardiovascular risk in patients with AS/axSpA regularly.
Management
Integrate cardiovascular risk assessment and modification into the management of AS/axSpA.
Monitoring & Follow-up
Ongoing cardiovascular surveillance is necessary for patients with high inflammatory activity.
Risks
Patients with extra-articular manifestations or long disease duration have increased cardiovascular risk.
Patient & Prescribing Data
Individuals with Ankylosing Spondylitis and Axial Spondyloarthritis.
Pharmacologic therapy may influence vascular and cardiac outcomes beyond musculoskeletal symptom relief.
Clinical Best Practices
Reassess cardiovascular risk as part of the overall management paradigm for AS/axSpA.
Consider the impact of systemic inflammation on cardiovascular health in treatment plans.
